DME Capital Management Portfolio holdings
DME Capital Management advises the Greenlight funds, buying shares it thinks are cheap and shorting ones it thinks are overpriced. It is a value-oriented firm that mostly goes long and short in listed stocks, with occasional macro and distressed debt investments. David Einhorn is its president and portfolio manager, and the firm began operations in 2010. Einhorn started the hedge fund Greenlight Capital in 1996.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Versigent PLC
VGNT
|
+$90.8M |
| 2 |
Fortune Brands Innovations
FBIN
|
+$89.8M |
| 3 |
PayPal
PYPL
|
+$64.8M |
| 4 |
Primo Brands
PRMB
|
+$62.7M |
| 5 |
Warner Bros
WBD
|
+$60.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Victoria's Secret
VSXY
|
+$105M |
| 2 |
Centene
CNC
|
+$57.8M |
| 3 |
SLM Corp
SLM
|
+$45M |
| 4 |
Versant Media Group
VSNT
|
+$44.4M |
| 5 |
Peloton Interactive
PTON
|
+$43.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 36.91% |
| 2 | Healthcare | 16.5% |
| 3 | Industrials | 11.95% |
| 4 | Energy | 10.38% |
| 5 | Communication Services | 7.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Green Brick Partners
GRBK
$2.71B
| $758M | 19.39% |
9,467,383
| – | – |
2024 Q1
9 quarters
|
|
2
Fluor
FLR
$6.47B
| $244M | 6.24% |
4,658,750
-88,600
| -2% | -$4.34M |
2025 Q2
4 quarters
|
|
3
Core Natural Resources Inc
CNR
$4.05B
| $183M | 4.67% |
2,283,200
+425,060
| +23% | +$37.7M |
2024 Q1
9 quarters
|
|
4
Brighthouse Financial
BHF
$2.55B
| $180M | 4.6% |
2,842,100
| – | – |
2024 Q1
9 quarters
|
|
5
Acadia Healthcare
ACHC
$3.59B
| $130M | 3.32% |
4,400,641
-117,740
| -3% | -$3.02M |
2024 Q4
6 quarters
|
|
6
PENN Entertainment
PENN
$2.48B
| $125M | 3.2% |
5,860,270
-184,170
| -3% | -$3.3M |
2024 Q1
9 quarters
|
|
|
7
Fortune Brands Innovations
FBIN
$5.9B
| $123M | 3.15% |
+2,241,875
| New | +$89.8M |
2026 Q2
0 quarters
|
|
8
PG&E
PCG
$29.1B
| $112M | 2.85% |
6,632,852
| – | – |
2025 Q3
3 quarters
|
|
|
9
Centene
CNC
$34.7B
| $106M | 2.71% |
1,651,150
-1,080,660
| -40% | -$57.8M |
2024 Q4
6 quarters
|
|
10
Graphic Packaging
GPK
$3.3B
| $105M | 2.69% |
9,953,430
+853,450
| +9% | +$8.71M |
2024 Q1
9 quarters
|
|
11
TD Synnex
SNX
$18.5B
| $102M | 2.61% |
381,042
-98,488
| -21% | -$23.7M |
2024 Q4
6 quarters
|
|
12
Teva Pharmaceutical Industries Limited
TEVA
$49.5B
| $97.8M | 2.5% |
2,886,059
-24,670
| -0.8% | -$822K |
2024 Q1
9 quarters
|
|
|
13
Versigent PLC
VGNT
$3B
| $95.7M | 2.45% |
+2,277,640
| New | +$90.8M |
2026 Q2
0 quarters
|
|
14
Capri Holdings
CPRI
$2.25B
| $89.5M | 2.29% |
4,820,118
-110,200
| -2% | -$2.12M |
2024 Q2
8 quarters
|
|
15
BKV Corp
BKV
$2.05B
| $84.7M | 2.17% |
3,095,173
+399,630
| +15% | +$11M |
2025 Q4
2 quarters
|
|
16
DHT Holdings
DHT
$3.36B
| $83.2M | 2.13% |
5,034,320
-238,450
| -5% | -$4.26M |
2024 Q1
9 quarters
|
|
17
Crocs
CROX
$7.3B
| $80.7M | 2.07% |
669,140
| – | – |
2026 Q1
1 quarter
|
|
18
Roivant Sciences
ROIV
$29.8B
| $76.2M | 1.95% |
2,152,669
| – | – |
2024 Q1
9 quarters
|
|
19
Sotera Health
SHC
$4.65B
| $73.4M | 1.88% |
4,135,515
+2,069,835
| +100% | +$32.6M |
2025 Q2
4 quarters
|
|
|
20
Versant Media Group
VSNT
$4.77B
| $69.2M | 1.77% |
1,922,172
-1,106,443
| -37% | -$44.4M |
2026 Q1
1 quarter
|
|
|
21
Primo Brands
PRMB
$8.7B
| $69M | 1.77% |
+2,823,660
| New | +$62.7M |
2026 Q2
0 quarters
|
|
22
Dauch Corp
DCH
$1.06B
| $67.2M | 1.72% |
12,395,104
+6,083,754
| +96% | +$37M |
2026 Q1
1 quarter
|
|
|
23
PayPal
PYPL
$48.8B
| $61.5M | 1.57% |
+1,424,320
| New | +$64.8M |
2026 Q2
0 quarters
|
|
24
Henry Schein
HSIC
$9.8B
| $60M | 1.54% |
718,550
+119,250
| +20% | +$9.12M |
2025 Q4
2 quarters
|
|
|
25
DELISTED
Warner Bros
WBD
| $59.9M | 1.53% |
+2,246,180
| New | +$60.8M |
2026 Q2
0 quarters
|
|
Similar funds
DME Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, DME Capital Management held 52 positions worth $3.91B, up 23% from $3.19B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
DME Capital Management deployed $269M of net new capital in Q2 2026, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Versigent PLC: 2,277,640 shares worth $95.7M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 37% of assets, down from 37% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Centene, an estimated $57.8M trimmed.
- DME Capital Management's largest Q2 2026 buy was Versigent PLC: 2,277,640 shares worth $95.7M.
- DME Capital Management added most to Core Natural Resources Inc in Q2 2026, an estimated $37.7M increase.
- DME Capital Management's biggest Q2 2026 reduction was Centene, cutting an estimated $57.8M.
- DME Capital Management fully exited Victoria's Secret in Q2 2026, selling an estimated $105M.
- DME Capital Management's ten largest holdings make up 53% of its $3.91B portfolio in Q2 2026.
- DME Capital Management opened 7 new positions and closed 6 in Q2 2026.
- DME Capital Management's portfolio value rose 23% quarter-over-quarter to $3.91B.
Based on DME Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.